Home » Stocks » CGEN

Compugen Ltd. (CGEN)

Stock Price: $8.91 USD -0.50 (-5.31%)
Updated Mar 3, 2021 4:00 PM EST - Market closed
Pre-market: $8.97 +0.06 (0.67%) Mar 4, 4:15 AM
Market Cap 794.36M
Revenue (ttm) 2.00M
Net Income (ttm) -29.70M
Shares Out 79.59M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $8.91
Previous Close $9.41
Change ($) -0.50
Change (%) -5.31%
Day's Open 9.56
Day's Range 8.66 - 9.67
Day's Volume 1,424,772
52-Week Range 5.94 - 19.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 5 days ago

ARK Investment Management – or ARK Invest, as it usually styles itself – had a great 2020. ARK Innovation ETF (ARKK), the firm's flagship fund, returned more than 150% last year.

Other stocks mentioned: AMZN, ARKK, EDIT
Benzinga - 6 days ago

Compugen Ltd (NASDAQ: CGEN) reports updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and a dose-escalation combination study with Bristol-Myers Squi...

PRNewsWire - 6 days ago

HOLON, Israel, Feb. 25, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial r...

Benzinga - 1 week ago

Compugen Ltd (NASDAQ: CGEN) expands its clinical collaboration agreement with Bristol-Myers Squibb Co (NYSE: BMY), wherein Bristol Myers will supply Opdivo (nivolumab) for Compugen's Phase 1b ...

PRNewsWire - 2 months ago

HOLON, Israel, Dec. 23, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today progress f...

Other stocks mentioned: AZN
PRNewsWire - 3 months ago

HOLON, Israel, Nov. 10, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that managem...

Seeking Alpha - 3 months ago

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

HOLON, Israel, Sept. 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the addit...

PRNewsWire - 5 months ago

HOLON, Israel, Sept. 8, 2020 /PRNewswire/ -- Compugen Ltd.

PRNewsWire - 6 months ago

HOLON, Israel, Sept. 3, 2020 /PRNewswire/ -- Compugen Ltd.

PRNewsWire - 6 months ago

HOLON, Israel, Aug. 28, 2020 /PRNewswire/ -- Compugen Ltd.

Seeking Alpha - 7 months ago

Compugen Ltd (CGEN) CEO Anat Dayag on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 7 months ago

HOLON, Israel, July 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today reported financial r...

Seeking Alpha - 7 months ago

Compugen: Clinical Data Supports COM701 As A Potential Breakthrough Cancer Treatment

PRNewsWire - 7 months ago

HOLON, Israel, July 16, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today that the C...

Seeking Alpha - 9 months ago

Compugen's Cancer Trial, And Other News: The Good, Bad And Ugly Of Biopharma

PRNewsWire - 9 months ago

HOLON, Israel, June 1, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U....

The Motley Fool - 9 months ago

Here are the hottest companies coming up in the biotech sector next month.

Other stocks mentioned: RHHBY, VRTX
Zacks Investment Research - 9 months ago

Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately.

Zacks Investment Research - 9 months ago

Compugen (CGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 9 months ago

Roche's Upcoming Phase 2 TIGIT Results At ASCO Could Read Through To Compugen's COM902 TIGIT Candidate

Zacks Investment Research - 9 months ago

Top Ranked Momentum Stocks to Buy for May 8th

Other stocks mentioned: CHGG, GNMK
Seeking Alpha - 9 months ago

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2020 Results - Earnings Call Transcript

The Motley Fool - 9 months ago

Its new discovery in the field of cancer immunotherapy produced mixed clinical results, but it certainly has ample backing from the big players.

Zacks Investment Research - 10 months ago

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 10 months ago

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

24/7 Wall Street - 11 months ago

When the financial markets enter their once-a-decade crisis mode, it often feels impossible to think rationally and to make normal investing decisions.

The Motley Fool - 11 months ago

Two patients treated with one of the biotech's drugs had partial responses.

Seeking Alpha - 1 year ago

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Compugen Ltd.: Upcoming Catalysts In 2020 And 2021

24/7 Wall Street - 1 year ago

With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be anoth...

Other stocks mentioned: GLUU, GME, GRPN, IDXG, MEET, OGI, RTIX, SYBX, ZNGA
Investopedia - 1 year ago

Compugen shares rebounded Thursday after Cantor Fitzgerald initiated coverage with an Overweight rating and a $10 price target.

Zacks Investment Research - 1 year ago

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

Other stocks mentioned: ACAD, CUE, EPZM, QURE
Zacks Investment Research - 1 year ago

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Seeking Alpha - 1 year ago

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 1 year ago

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 1 year ago

Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q1 2019 Results - Earnings Call Transcript

About CGEN

Compugen, a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its thera... [Read more...]

Industry
Biotechnology
IPO Date
Aug 11, 2000
CEO
Dr. Anat Cohen-Dayag
Employees
68
Stock Exchange
NASDAQ
Ticker Symbol
CGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Compugen stock is "Strong Buy." The 12-month stock price forecast is 21.71, which is an increase of 143.66% from the latest price.

Price Target
$21.71
(143.66% upside)
Analyst Consensus: Strong Buy